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Protamine nanoparticles were designed by encapsulating small hairpin RNA (shRNA)-expressing plasmid DNA targeting
the Bcl-2 gene (shBcl-2) to silence apoptosis-related Bcl-2 protein for improving the transfection efficiency and cytotoxicity
in cancer therapy. Our findings demonstrated that the obtained protamine nanoparticles possessed excellent characterizations
of small particle size, homogenous distribution, positive charge, and high encapsulation efficiency of gene. shBcl-2
loaded in nanoparticles (NPs) was protected effectively from the degradation of DNase I and serum. More importantly,
it significantly improved the efficiency of transfection of shRNA in vitro in A549 cells and increased its cytotoxicity and
induced more cell apoptosis by silencing Bcl-2.
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Although traditional therapies such as surgery, radio-
therapy, chemotherapy, and other traditional means can
improve the curing effects in the early stage of cancer
patients in some extent, it seemed unvalued to fight
against metastasis, recurrence of tumor, and the treat-
ment of advanced cancer. It was well known that some
genes such as oncogenes and cell apoptosis-related
genes including Bcl-2 were highly expressed in tumor
cells and facilitated the cell unlimited reproduction and
carcinogenesis [1-4]. Therefore, the cancer therapy based
on silencing the specific gene such as Bcl-2 for killing
tumor cells becomes a new and potential application in
tumor treatment [5-9].
Nanoparticles as a gene carrier showed their special
merits compared to other traditional drug delivery sys-
tems [10,11]. Firstly, it can efficiently encapsulate DNA,
RNA, peptide nucleic acid (PNA), and double-stranded
RNA (dsRNA) and prevent them from degradation by
enzymes [12]. Secondly, duo to the small particle size,
nanoparticles could easily escape from tumor vessels
and be kept around tumor tissue for longer time known
as enhanced permeability and retention effect (EPR),
thus favoring the accumulation and distribution of drugs* Correspondence: lyyxchengwei@163.com; liangzhao79@163.com
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in any medium, provided the original work is p[13]. More importantly, nanoparticles as a whole were
internalized into cells though endocytosis and avoided
contact between gene and proteins situated at the sur-
face of cells, leading to the significant improvement on
the transfection efficiency of gene [14-16].
Protamine, as a kind of basic protein, acts on combining
with DNA in fish in the mature sperm nucleus. The rela-
tive molecular mass of protamine is about 6,000 ~ 10,000
and consisting of 30 amino acid residues in which two
thirds is the arginine. Toxicological experiments have
proved its excellent biocompatibilities including nontoxi-
city, harmlessness, good stability, and heating solidifica-
tion [17,18]. Interestingly, protamine contains a nuclear
localization signal (NLS); it and its binding partners can
be transported into the nucleus, improving the efficiency
of exogenous substances into the cell nucleus [19,20].
In this work, protamine nanoparticles as a gene carrier
were prepared by desolvation method and the mass ratio
between gene and protamine was also optimized by deter-
mining their particle size, zeta potential, and morphology.
The small hairpin RNA (shRNA)-expressing plasmid
DNA targeting the Bcl-2 gene (shBcl-2) as a model gene
was encapsulated in nanoparticles (NPs) to treat cancer
more efficiently. The in vitro transfection efficiency, cyto-
toxicity, and western blot were investigated in lung cancer
cell A549.Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Protamine was purchased from Tianjin Sixth Pharmaceutical
Co., Ltd (Tianjin, China), 3-(4,5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide and proteinase K were
obtained from Sigma-Aldrich (St. Louis, MO, USA), and
pGCsi-U6/Neo/GFP-Bcl-2 shRNA-expressing plasmid
DNA (pDNA) (Bcl-2 shRNA, shBcl-2) which targeted
Bcl-2 mRNA sequence (GATGAAGTACATCCATTAT)
and pGCsi-U6/Neo/GFP-shRNA-expressing pDNA
(pEGFP) were purchased from Genechem Co., Ltd.
(Shanghai, China). All other chemicals purchased were of
analytical grade and were obtained from a variety of ven-
dors. A549 cells were obtained from Liaoning Medical
University.The preparation and characterization of shBcl-2-loaded
protamine NPs
Certain amount of protamine was swelled with distilled
water overnight to obtain an aqueous solution containing
protamine at 1.5, 2.5, and 4 mg/mL. After that, the shBcl-2
was also added into the obtained protamine solution
followed by the addition of 1 mL of ethanol at 37°C under
continuous stirring (1,000 rpm). The resulting white sus-
pension was further stirred for 24 h, and then ethanol was
removed with vacuum distillation succeeded by the
addition of 8% glutaraldehyde in water (0.5 μL per mg of
protamine) for particle cross-linking. After washing with
cold PBS three times, the resulting nanoparticles with dif-
ferent mass ratio of protamine and shBcl-2 (50:1, 100:1,
and 200:1) were purified and sterilized by filtration using
Millex GP Filter Unit (0.22 μm, Millipore, Billerica, MA,
USA). The characterization of shBcl-2-loaded NPs was in-
vestigated to determine the particle size and zeta potential
by using dynamic light scattering (DLS) (NanoZS, Malvern
Instruments, Malvern, UK), and the morphology of parti-
cles was observed by using transmission electron micro-
scope (TEM) (Jeol, Tokyo, Japan). The difference between
the amount of the initially added shRNA and shRNA in
the supernatant was measured at detecting absorbance at
260 nm using a UV/Vis spectrophotometer (model 1601,
Shimadzu, Kyoto, Japan) to determine the encapsulation
efficiency (EE) of shRNA in nanoparticles.Gel retardation experiments with shBcl-2-loaded NPs
The obtained NPs were collected and the shRNA in the
supernatant was removed by centrifugation at 16,000 rpm.
The collected NPs were degraded by incubating with a
medium containing 400 μL of cell lysates, 200 μL of SDS
(10%), and 100 μL of proteinase K (Sigma-Aldrich) solu-
tion (20 mg/mL) at 57°C overnight, and shRNA loaded in
NPs was extracted with phenol-chloroform-isoamyl butyr-
ate method and analyzed by agarose gel electrophoresis.DNase I protection test
The collected NPs were added into 10 μL of buffer con-
taining 2 U of DNase I and replenish to 50 μL with
nuclease-free water for continuous incubation at 37°C for
1 h. As 1 μL of stop buffer was added into the medium to
stop the reaction, shRNA from NPs was extracted accord-
ing to the above method and the products were analyzed
by agarose gel electrophoresis. At the same time, the
naked shRNA was treated by the same method as a con-
trol treatment.
Serum protection test
NPs were immersed in cell culture medium containing
10% fetal bovine serum and continue to incubate at 37°C
for 8 h. NPs were collected and shRNA was extracted
according to the procedure described in ‘Gel retardation
experiments with shBcl-2-loaded NPs’ section and were
analyzed by agarose gel electrophoresis. At the same
time, the naked shRNA was also treated by the same
method as a control treatment.
In vitro transfection experiments
Enhanced green fluorescent protein (EGFP) was used as
the reporter gene to compare the transfection efficiency
of free EGFP and EGFP-loaded NPs. After adherence of
A549 cells at a density of 5 × 104/mL, free EGFP and
EGFP-loaded NPs containing the same concentration of
EGFP were added into the culture medium and incu-
bated with cells for 48 h. After that, the supernatant was
discarded after centrifugation and cells in well were
washed with ice-cold PBS for three times for the obser-
vation of their images with fluorescent microscopy
(DMI400B, Leica Microsystems, Wetzlar, Germany).
In vitro cell viability assay
A 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide (MTT, Sigma-Aldrich) assay was used to com-
pare cell inhibiting effects in A549 cells treated with free
shBcl-2 and shBcl-2-loaded NPs. Cells were seeded into
the 96-well plate (100 μL each well) for cellular adher-
ence at 37°C under 5% CO2 and 95% O2. After that, free
shBcl-2 and shBcl-2-loaded NPs at different amounts were
separately incubated with cells for 24 h followed by the
addition of 20 μL MTT with concentration of 5 mg/mL
and continued to be incubated for 4 h at 37°C. Then, the
supernatant was aspirated, 150 μL of DMSO was added to
each well, and the absorbance was measured at 490 nm
using a microplate reader (iMark™, Bio-Rad, Hercules,
CA, USA).
Western blot assay
Cells were treated with free shBcl-2 and shBcl-2-loaded
protamine NPs and washed twice with ice-cold PBS, and
then lysed in RIPA buffer (150 mM NaCl, 1% NP-40, 1%
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50 mM Tris-Cl, pH 7.4). About 50 μg protein in 20 μL
of cell lysate separated by 10% SDS-PAGE was trans-
ferred onto polyvinylidene fluoride (PVDF) membrane.
After treatment with 1% BSA for blocking, the primary
antibodies (Bcl-2, caspase-3, poly ADP ribose polymer-
ase (PARP)) were incubated with the PVDF membrane
at 4°C, overnight, followed by continuous incubation
with secondary antibody for 1 h and stained with ECL.
The levels of the targeted proteins were photographed
and analyzed by UVP gel analysis system (iBox Scientia
600; UVP, LLC., Upland, CA, USA).
Results
The characterization of shBcl-2-loaded NPs
The morphology and size distribution of the prepared
nanoparticles were determined by TEM and DLS, and
the results were displayed in Table 1. It can be seen from
Table 1 that with the increasing amount of protamine,
the particle size was enhanced and the zeta potential also
continued to rise. In term of encapsulation efficiency of
shBcl-2 in NPs, about 85% of shBcl-2 was loaded in NPs
with the mass ratio at 100:1 in contrast with the other two
NPs. Judging by the TEM in Figure 1, it was observed that
shBcl-2-loaded NPs with different mass ratios possessed
an excellent characterization of suitable particle size,
homogenous size distribution, and high monodispersion,
indicating that shBcl-2-loaded NPs with the mass ratio of
100:1 was a potential optimized gene carrier with good
characterization and higher encapsulation efficiency.
Stability and protecting effects of shBcl-2-loaded NPs
Positive-charged NPs can encapsulate negative-charged
shRNA owing to the strong electrostatic attraction. With
the increase of amount of shRNA in NPs, the electro-
phoretic mobility of DNA is faster and the band will be
stronger. The results in Figure 2 showed that when the
ratio of protamine and DNA was 100:1, the binding abil-
ity of shRNA with NPs was the strongest among the
three groups, suggesting that more shRNA was en-
trapped in NPs.
In order to investigate the protection of NPs from the
degradation of shRNA, DNase I protection test and
serum protection test were performed in vitro. The re-
sults showed that after the naked shRNA was digested
by DNaseI for 1 h or incubated with fetal bovine serum
for 8 h, the band disappeared suggesting that the nakedTable 1 Key parameters of shBcl-2-loaded NPs
Group Diameter (nm) Zeta potentia
shBcl-2-loaded NPs (50:1) 82 ± 9 +5.67 ± 0.94
shBcl-2-loaded NPs (100:1) 108 ± 15 +10.32 ± 2.67
shBcl-2-loaded NPs (200:1) 298 ± 30 +13.68 ± 3.43shRNA was degraded thoroughly. In contrast, after diges-
tion, the band of shRNA loaded in NPs still remained, im-
plying that nucleic acid in NPs was not degraded and
retained the integrate structure. It suggested that shRNA
was efficiently protected from the enzyme’s degradation
by encapsulation in NPs.
Cytotoxicity
The inhibiting effects of free shBcl-2 and shBcl-2-loaded
NPs on the amplification of A549 cells were determined
by MTT assay. It can be seen from Figure 3 that shBcl-2-
loaded NPs showed higher cytotoxicity at different con-
centration than free shBcl-2, suggesting that more shBcl-2
in NPs were transported into cells with the mediation of
internalization of NPs. It also indicated that different from
penetration of free drug into cells, cellular uptake of
shBcl-2-loaded NPs may depend on endocytosis and
macropinocytosis and induced the sufficient internaliza-
tion of NPs in cells. Therefore, cytotoxic effects of shBcl-
2-loaded NPs were higher than those of free shBcl-2.
In vitro transfection effects
To evaluate the in vitro transfection effects of NPs, EGFP-
loaded NPs were observed using the fluorescent images of
cells. The images (Figure 4) showed that compared with
free EGFP, cells treated with EGFP-loaded NPs showed
the stronger green fluorescent color within 48 h. In
addition, with the increase of the amount of EGFP in NPs,
the intracellular green fluorescence intensity was in-
creased. It demonstrated that the in vitro EGFP entrapped
in NPs facilitated the cellular accumulation and avoided
the extracellular degradation, thus leading to significant
improvement on the in vitro transfection effects.
Western blot analysis
It can be seen from Figure 5 that compared with control
and free shBcl-2, shBcl-2-loaded NPs inhibited the expres-
sion of Bcl-2 proteins significantly in A549 cells. We also
detected the PARP and caspase-3 as the main apoptosis
proteins to evaluate the apoptosis effects of cells induced
by silencing Bcl-2. It demonstrated that the expression of
caspase-3 was higher in cells treated with shBcl-2-loaded
NPs than in those treated with free Bcl-2, indicating that
shBcl-2-loaded NPs induced the higher apoptosis of A549
cells by silencing the Bcl-2 proteins and increasing the ex-
pression of caspase-3.l (mV) Polydispersity Encapsulation efficiency (%)
0.21 ± 0.07 60.98 ± 2.46
0.15 ± 0.08 85.42 ± 3.87
0.20 ± 0.04 68.78 ± 4.67
Figure 1 TEM images of NPs. shBcl-2-loaded NPs (50:1) (A), shBcl-2-loaded NPs (100:1) (B), and shBcl-2-loaded NPs (200:1) (C). DLS analysis of
the obtained shBcl-2-loaded NPs (D).
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Basing on the electric attraction between positive and
negative charges, negative-charged shRNA with high
water solubility tended to encapsulate into the core of
protamine nanoparticles with the positive-charged one.Figure 2 Combining ability and protecting effects of shBcl-2-loaded NPs
loading ability of shBcl-2 in NPs (A), DNaseI protection of shBcl-2-loaded N
shBcl-2; lanes 2 to 4, shBcl-2-loaded NPs prepared at mass ratios of 50,100,Compared with the disadvantages of naked shRNA such
as fast degradation, short half-life, and difficulty in pene-
trating the cell membrane owing to the negative charge,
gene-loaded protamine nanoparticles with the positive
charges facilitated the internalization of cells throughby agarose gel electrophoresis. Gel retardation assay for determining
Ps (B), and serum protection of shBcl-2-loaded NPs (C). (Lane 1: naked
and 200, respectively).
Figure 3 Viability of A549 cells after treatment with free shBcl-2
and shBcl-2-loaded NPs. Viability of A549 cells after treatment with free
shBcl-2 and shBcl-2-loaded NPs with the concentrations of shBcl-2 at 6, 10,
and 15 ng/μL. *P<0.05, vs the free shBcl-2 group treated with A549 cells.
Figure 4 In vitro transfection efficiency of EGFP-loaded NPs. In vitro transfection efficiency of EGFP-loaded NPs was investigated by observing
the microscopic images of A549 cells after incubation with free EGFP and EGFP-loaded NPs within 48 h ((A) free EGFP at 2 μg each well, (B) NPs
loading EGFP of 2 μg each well, and (C) NPs loading EGFP of 4 μg each well).
Figure 5 Western blot analyses of the expression levels of Bcl-2,
caspase-3, and PARP proteins. Western blot analyses of the expression
levels of Bcl-2, caspase-3, and PARP proteins in A549 cells after incubating
with free shBcl-2 and shBcl-2 loaded NPs.
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transfection of shRNA in vitro in A549 cells [21,22].
Moreover, shRNA entrapped inside of NPs was isolated
from the enzymes in the blood and cytoplasm in the
transmitting process, thus improving its stability and
curing effects.
The occurrence of tumor may have originated from
cell proliferation and excessive inhibited apoptosis of
tumor cells; Bcl-2 protein as the founding member of
the Bcl-2 family of regulator proteins played a big role
on regulating cell death (apoptosis), by either inducing it
(pro-apoptotic) or inhibiting it (anti-apoptotic). Exogen-
ous dsRNA in vivo is cut into 21- to 23-nt small interfer-
ing RNA (siRNA) and bonds to the RNase complexes to
form gene RNA-induced silencing complex (RISC)
[23,24]. With the mediation of ATP, double-stranded
siRNA was depolymerized into single strands and partici-
pated in the transcription of the gene homologous se-
quences, thus eventually leading to gene silencing. The
result showed that compared with naked shBcl-2, shBcl-2-
loaded protamine nanoparticles significantly inhibited the
expression of Bcl-2 proteins, thus improving their cyto-
toxic ability and inducing the cell apoptosis.Conclusions
We used protamine as the material to prepare gene-
carried nanoparticles and investigated its applicability
and feasibility for improving shRNA-mediated anti-
cancer effects. The mass ratio of protamine and gene
was also optimized basing on their physicochemical and
biological properties. The results showed that shBcl-2-
loaded protamine nanoparticles with a mass ratio of
100:1 possessed the excellent characterization with suit-
able particle distribution, positive charge, and higher en-
capsulation efficiency of shRNA. Compared with naked
shRNA, nanoparticles could effectively protect shRNA
from being degraded by nuclease and serum. More im-
portantly, it significantly improved the transfection of
shRNA in vitro in A549 cells. shBcl-2-loaded protamine
nanoparticles increased their cytotoxicity of A549 and
induced cell apoptosis by silencing Bcl-2. Taken together,
protamine nanoparticle could be a promising nonviral
nanodevice for improving the targeting delivery of gene
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